Addex Therapeutics to Release Q1 2024 Financial Results and Host Conference Call on June 6, 2024
May 31 2024 - 1:00AM
Geneva, Switzerland, May 31, 2024
- Addex Therapeutics (SIX and Nasdaq: ADXN), a
clinical-stage biopharmaceutical company focused on developing a
portfolio of novel small molecule allosteric modulators for
neurological disorders, announced today that it will issue its Q1
2024 Financial Results on June 6, 2024. Tim Dyer, CEO and Mikhail
Kalinichev, Head of Translational Science, will provide a business
update and a review of the Addex product pipeline during a
teleconference and webcast for investors, analysts and media at
16:00 CEST (15:00 BST / 10:00 EDT / 07:00 PDT) the same day.
Title: Addex Therapeutics to release Q1 2024 financial results
and provides corporate update Date: June 6, 2024Time: 16:00 CEST
(15:00 BST / 10:00 EDT / 07:00 PDT)
Joining the Conference Call:
- Participants are required to register in advance of the
conference using the link provided below. Upon registering, each
participant will be provided with Participant Dial-in numbers, and
a unique Personal PIN.
- In the 10 minutes prior to the call’s start time, participants
will need to use the conference access information provided in the
e-mail received at the point of registering. Participants may also
use the call me feature instead of dialing the nearest dial in
number.
Webcast registration
URL:https://edge.media-server.com/mmc/p/5twaqd3r
Conference call registration URL:
https://register.vevent.com/register/BI042149b2b22741eb96c2d718ff2853bb
About Addex:
Addex Therapeutics is a clinical-stage
biopharmaceutical company focused on developing a portfolio of
novel small molecule allosteric modulators for neurological
disorders. Addex’s lead drug candidate, ADX71149 (mGlu2 positive
allosteric modulator or PAM), developed in collaboration with
Janssen Pharmaceuticals Inc., has recently completed a Phase 2
clinical study for the treatment of epilepsy. The Company’s second
clinical program, dipraglurant (mGlu5 negative allosteric modulator
or NAM), is under evaluation for future development in dyskinesia
associated with Parkinson’s disease and post-stroke/TBI recovery.
Addex partnership with Indivior on GABAB PAM is advancing multiple
drug candidates through clinical candidate selection for substance
use disorder. Under the agreement with Indivior, Addex is advancing
an independent GABAB PAM program for chronic cough through clinical
candidate selection. Addex also holds a 20% share in a private
company, Neurosterix LLC which is advancing a portfolio of
allosteric modulator programs including M4PAM for schizophrenia,
mGlu7NAM for stress related disorders and mGlu2NAM for mild
neurocognitive disorders. Addex shares are listed on the SIX Swiss
Exchange and American Depositary Shares representing its shares are
listed on the NASDAQ Capital Market, and trade under the ticker
symbol “ADXN” on each exchange. For more information, visit
www.addextherapeutics.com
Contacts:
Tim DyerChief
Executive OfficerTelephone: +41 22 884 15
55PR@addextherapeutics.com |
Mike
SinclairPartner, Halsin Partners+44 (0)7968
022075msinclair@halsin.com |
Addex Forward Looking Statements:
This press release contains forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995, as amended, including statements about the
intended use of proceeds of the offering. The words “may,” “will,”
“could,” “would,” “should,” “expect,” “plan,” “anticipate,”
“intend,” “believe,” “estimate,” “predict,” “project,” “potential,”
“continue,” “target” and similar expressions are intended to
identify forward-looking statements, although not all
forward-looking statements contain these identifying words. Any
forward-looking statements in this press release, are based on
management's current expectations and beliefs and are subject to a
number of risks, uncertainties and important factors that may cause
actual events or results to differ materially from those expressed
or implied by any forward-looking statements contained in this
press release, including, without limitation, uncertainties related
to market conditions. These and other risks and uncertainties are
described in greater detail in the section entitled “Risk Factors”
in Addex Therapeutics’ Annual Report on Form 20-F for the year
ended December 31, 2023, as filed with the SEC on April 18, 2024,
the final prospectus supplement and accompanying prospectus and
other filings that Addex Therapeutics may make with the SEC in the
future. Any forward-looking statements contained in this press
release represent Addex Therapeutics’ views only as of the date
hereof and should not be relied upon as representing its views as
of any subsequent date. Addex Therapeutics explicitly disclaims any
obligation to update any forward-looking statements.
Addex Therapeutics (NASDAQ:ADXN)
Historical Stock Chart
From Jul 2024 to Aug 2024
Addex Therapeutics (NASDAQ:ADXN)
Historical Stock Chart
From Aug 2023 to Aug 2024